Placeholder canvas

April 2022 Top Biopharma Deal: Harbour BioMed – AstraZeneca Bispecific Antibody for Cancer Treatment

May 9, 2022 | Deal of the Month, Partnership Deals

April 2022 Top Biopharma Deal Upfront
Harbour BioMed development and commercialization deal with AstraZeneca for solid tumors

Highlighted Deal Financial Comps

Date Announced:

April 6, 2022

Total Deal Value:


Upfront Cash:


Upfront Equity:


Option Payments:


Total Milestones:

up to $325M


Undisclosed tiered royalties

Cost & Profit Split:


Deal Synopsis

The Asset:

Harbour BioMed’s HBM7022 CLDN18.2xCD3 bispecific antibody for solid tumors, including gastric and pancreatic cancers

Deal Structure:

Development and Commercial License

Partnership Features:

Collaborative Development, No Shared Cost

Deal Details:

  • Harbour BioMed granted AstraZeneca exclusive, worldwide rights to develop and commercialize its HBM7022 CLDN18.2xCD3 bispecific antibody developed using HBM’s HCAb based Immune Cell Engagers (HBICE) platform for the treatment of solid tumors, including gastric and pancreatic cancer.
  • AstraZeneca will be responsible for all costs for development and commercialization.
  • HBM will receive $25M up front and is eligible for up to $325M in development, regulatory, and commercial milestones, plus undisclosed tiered royalties.

Last Month:

Congrats to Harbour BioMed and AstraZeneca for landing DealForma’s April 2022 Top Biopharma Deal. Last month’s Deal of the Month was IGM Biosciences – Sanofi IgM antibody platform for Cancer and immunology/inflammation treatment. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.

We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting to schedule your personalized demo.


Licensing Deals


Funding Rounds




Company Profiles


Other Deals


Drug Sales Figures

All of this by stage, disease indication, modality, target...

More Research by DealForma

Biopharma Venture Investment Through Q3 2023

Biopharma Venture Investment Through Q3 2023

Biopharma venture investment totals rebounded in Q3 2023, nearing 2020 quarterly levels. The number of rounds, especially for seed and Series A, are still depressed as we are seeing investors re-investing in later rounds of portfolio companies rather than new...

Biopharma M&A Through Q3 2023

Biopharma M&A Through Q3 2023

This is a quick readout of biopharma M&A activity through Q3 2023 as we track the prominent deals for the year leading up to year-end. Among some of the largest in biopharma are Novo Nordisk's acquisition of Inversago Pharma offering shareholders up to $1.075...

Biopharma R&D Partnerships – Q3 2023 Review

Biopharma R&D Partnerships – Q3 2023 Review

Biotech, pharma, and medtech R&D partnerships in Q3 2023 settled to pre-2020 levels on total deal announced values but again on fewer deals. Major deal announcements in Q3 included Pfizer / Flagship Pioneering, Alnylam / Roche, Nanobiotix / Janssen, Orionis /...